# A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC

Source: https://onco.cc/trials/nct07798947/  
OnCo record `nct07798947` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of adebrelimab in lung cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC is a phase 2, interventional study registered as NCT07798947 by Shanghai Hengrui Pharmaceutical Co., Ltd., with a registry enrolment figure of 120 participants, started 2026-09 and due to reach its primary completion in 2028-12. Interventions recorded: SHR-7787 Injection; SHR-1316. Conditions listed: Limited-stage Small-cell Lung Cancer. Primary outcome: Incidence and severity of adverse events (AEs); Incidence and severity of serious adverse events (SAEs); Progression-Free Survival (PFS). Lung eligibility wording from the registry: "Histologically or cytologically confirmed unresectable limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemotherapy and radiation therapy". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07798947
- Phase: 2
- Setting: A Multicenter, Open-label, Phase II Clinical Study of SHR-7787 Injection Combined With Adebrelimab in Patients With Limited Stage Small Cell Lung Cancer
- Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07798947: https://clinicaltrials.gov/study/NCT07798947

## Connected records

- cancers: [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07798947.json